• Vaccine Name: M. tuberculosis HBHA Protein Vaccine
• Target Pathogen: Mycobacterium tuberculosis
• Target Disease: Tuberculosis
• Vaccine Ontology ID: VO_0004059
• Type: Subunit vaccine
• Status: Research
• Antigen: HBHA
• HBHA gene engineering:
  • Type: Recombinant protein preparation
  • Description:
  • Detailed Gene Information: Click Here.
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001250
  • Description: DDA-MPL
• Adjuvant:
  • Adjuvant name:
  • VO adjuvant ID: VO_0001261
• Immunization Route: subcutaneous injection

Mouse Response

• Host Strain: C57BL/6
• Vaccination Protocol: were vaccinated subcutaneously three times with 5 μg of either HPLC-purified HBHA (nHBHA) or recombinant HBHA emulsified in 150 μg of dimethyldioctadecylammonium bromide (DDA) (Acros Organics, Morris Plains, N.J.)-monophosphoryl lipid A (MPL) adjuvant or with the adjuvant combination alone (Parra et al., 2004).
• Challenge Protocol: Mice were challenged with aerosolized M. tuberculosis Erdman (200 CFU) 4 weeks following the final immunization (Parra et al., 2004).
• Efficacy: The HBHA-containing vaccine gave a approximately 0.7-log reduction in CFU in both mouse lungs and spleens compared to adjuvant controls 28 days following challenge (Parra et al., 2004).
• Host Ifng (Interferon gamma) response
  • Description: There was a ~10-fold increase in the amount of IFN-γ released in the ex vivo assay by spleen cells from HBHA-immunized mice compared to cells from naïve mice or mice immunized with only adjuvant, which was a significantly higher amount. Splenocytes from immunized mice were incubated with murine BMMΦ infected with M. bovis BCG for 72 hours. Lymph node-derived lymphocytes from HBHA-vaccinated mice released approximately eightfold more IFN-γ in the presence of HBHA-stimulated macrophages than cells from naïve or adjuvant control mice released, which was also significant (Parra et al., 2004).
  • Detailed Gene Information: Click Here.
• Information about this animal model: Mouse Model for TB research